中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

The Chinese Early-onset Hypertension Study (CHESS)

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态招聘中
赞助商
China National Center for Cardiovascular Diseases

关键词

抽象

Hypertension (HTN) is the most important cardiovascular risk factor which is responsible for 50% of cardiovascular morbidity and mortality, and also a substantial public health problem affecting approximately 1/4 of the adult population in industrialized societies and over 1 billion people worldwide. Chronically elevated blood pressure without well control puts people at increased risk of target organ damages, including stroke, myocardial infarction, congestive heart failure, end-stage renal disease, blindness, and death. Especially, these damages are dramatically more severe in the early-onset hypertensive population.

描述

In this study, the hypertensive individuals are consecutively recruited from multiple centers, with an early onset age (less than 40 when diagnosed). A complete clinical history (information on history of hypertension, demographic characteristics, personal and family medical history) are collected by a trained staff using a standardized questionnaire on the first day of baseline observation, and physical examination are also collected in a standard procedure. Blood samples are collected after 12-hour overnight fast and biological variables are determined. Genomic DNA is isolated from leukocytes according to a standard procedure. The individuals will receive follow-up in an ordinal system. The investigators will focus on the clinical and genetic features, genotype-phenotype correlations and influencing factors of prognosis in Chinese early-onset hypertension patients.

日期

最后验证: 12/31/2017
首次提交: 05/19/2016
提交的预估入学人数: 06/28/2016
首次发布: 06/29/2016
上次提交的更新: 01/06/2018
最近更新发布: 01/08/2018
实际学习开始日期: 09/30/2012
预计主要完成日期: 11/30/2020
预计完成日期: 11/30/2020

状况或疾病

Hypertension

-

手臂组

干预/治疗
early-onset hypertension
early-onset hypertension patients recruited in Chinese multiple centers

资格标准

有资格学习的性别All
取样方式Non-Probability Sample
接受健康志愿者
标准

Inclusion Criteria:

- In accordance with the diagnosis of hypertension (BP≥140/90mmHg), and less than 40 years when diagnosed

Exclusion Criteria:

-

结果

主要结果指标

1. primary mortality of early-onset hypertension [through study completion, an average of 5 years]

the primary mortality of early-onset hypertension

次要成果指标

1. secondary outcomes of heart [through study completion, an average of 5 years]

The incidence rate of left ventricular hypertrophy, myocardial infarction, congestive heart failure, and arrhythmia.

2. secondary outcomes of brain [through study completion, an average of 5 years]

The incidence rate of stroke (include cerebral hemorrhage and cerebral ischemia)

3. secondary outcomes of kidney [through study completion, an average of 5 years]

The incidence rate of hypertensive renal injure and end-stage renal disease

4. secondary outcomes of eyes [through study completion, an average of 5 years]

The incidence rate of hypertensive eye injure

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge